Drug Profile
NNI 351
Alternative Names: NNI-351Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Neuronascent
- Class Anxiolytics; Behavioural disorder therapies; Small molecules
- Mechanism of Action DYRK kinase inhibitors; Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Attention-deficit hyperactivity disorder; Fragile X syndrome
- No development reported Down syndrome; Post-traumatic stress disorders
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Down syndrome in USA (PO)
- 28 Sep 2022 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders in USA (PO)
- 01 Jun 2022 NNI 351 receives Orphan Drug status for Fragile X syndrome in USA